Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Anticipated Size Of The Biomarker Clinical Phase Outsourcing Services Market Over The Five-Year Period 2025–2029?
The biomarker clinical phase outsourcing services market has seen substantial expansion in recent years. Its valuation is set to increase from $9.71 billion in 2024 to $11.91 billion in 2025, achieving a compound annual growth rate (CAGR) of 22.7%. This historical progression is largely due to factors like expanding government initiatives and financial backing, broader diagnostic uses for biomarkers, augmented government investment in research and development, quick technological leaps in areas such as genomics, proteomics, and imaging, and the rising need for cancer biomarkers.
The biomarker clinical phase outsourcing services market size is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $25.87 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 21.4%. This projected growth is attributed to the increasing application of biomarkers across various stages of clinical trials, the expanding use of biomarkers in clinical trials, the rising demand for precision medicines, the growing adoption of companion diagnostics, and the increasing need for personalized medicine. Noteworthy trends for the forecast period include the integration of advanced parameters in trials, clinical phases with a diagnostic focus, rapid progress in biomarker technology, increased government initiatives and funding, and overall technological advancements.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15740&type=smp
What Are The Key Drivers Of Growth In The Biomarker Clinical Phase Outsourcing Services Market?
An anticipated increase in clinical trials is set to fuel the expansion of the biomarker clinical phase outsourcing services market in the future. These trials represent research endeavors involving human subjects, designed to assess the safety and efficacy of novel medical treatments, interventions, or diagnostic methodologies. This increase in clinical trials is driven by progress in medical research, a growing incidence of chronic conditions, enhanced financial backing from public and private entities, and an escalating need for cutting-edge treatments and therapies. Specialized knowledge and experience in the areas of biomarker discovery, validation, and analysis are frequently possessed by outsourcing companies. Such expertise is capable of improving the quality and dependability of biomarker data gathered throughout the trial process. For example, data from the United States National Library of Medicine indicates that by May 2023, the number of registered clinical trials grew from 399,499 in 2022 to 437,533, spanning all 50 states and 221 countries. Additionally, reports showed that 140,492 studies (31%) were registered exclusively within the United States, while 241,498 studies (53%) were documented in non-U.S. locations. Consequently, the increased volume of clinical trials is poised to propel the development of the biomarker clinical phase outsourcing services market.
Which Key Segments Fueling The Biomarker Clinical Phase Outsourcing Services Market?
The biomarker clinical phase outsourcing servicesmarket covered in this report is segmented –
1) By Type: Surrogate Endpoints; Predictive Biomarker; Prognostic Biomarker; Safety Biomarker; Other Biomarker Types
2) By Service Type: Biomarker Validation; Biomarker Testing Services; Biomarker Sample Analysis
3) By Therapeutic Area: Oncology; Neurology; Cardiology; Autoimmune Diseases; Other Therapeutic Areas
4) By End-User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutions
Subsegments:
1) By Surrogate Endpoints: Tumor Marker-Based Endpoints; Imaging-Based Endpoints; Genetic or Genomic Markers
2) By Predictive Biomarker: Genetic Predictive Biomarkers; Protein Predictive Biomarkers; Metabolomic Predictive Biomarkers
3) By Prognostic Biomarker: Cancer Prognostic Biomarkers; Cardiovascular Prognostic Biomarkers; Neurological Prognostic Biomarkers
4) By Safety Biomarker: Toxicity Biomarkers; Adverse Drug Reaction Biomarkers; Drug Interaction Biomarkers
5) By Other Biomarker Types: Inflammation Biomarkers; Infectious Disease Biomarkers; Autoimmune Disease Biomarkers
How Are Emerging Market Trends Shaping The Biomarker Clinical Phase Outsourcing Services Industry Landscape?
Major entities within the biomarker clinical phase outsourcing services are prioritizing advancements in high-throughput flow cytometry and ELISpot testing to achieve a competitive edge in the market. High-throughput flow cytometry and ELISpot testing are utilized for biomarker analysis, delivering rapid and precise evaluations of immune responses and cellular markers. For instance, in November 2022, Celerion Inc., a US-based biotechnology outsourcing services company, expanded its service offerings to include GLP/GCP-compliant molecular and cell biology testing. This strategic initiative aims to bolster Celerion’s capabilities in assisting clients throughout the drug development process, from initial clinical research to regulatory submissions. By incorporating GLP/GCP-compliant molecular and cell biology tests, such as pharmacokinetic (PK), pharmacodynamic (PD), and biomarker analysis, Celerion can now provide a more extensive array of services. This expansion allows Celerion to support clients in producing high-quality data that meets regulatory requirements, thereby accelerating the development of new medicines.
Which Key Market Players Are Investing In Expansion And Innovation Of Biomarker Clinical Phase Outsourcing Services Market?
Major companies operating in the biomarker clinical phase outsourcing services market are Thermo Fisher Scientific Inc., Labcorp Drug Development Inc., ICON plc, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Syneos Health Inc., Intertek Group plc, Charles River Laboratories International Inc., Parexel International Corporation, QIAGEN N.V., Medpace Inc., Bioclinica Inc., Evotec SE, GenScript Biotech Corporation, Precision for Medicine Inc., BioAgilytix Labs LLC, Celerion Inc., Frontage Laboratories Inc., SomaLogic Inc., Selvita S.A., BioIVT LLC, Discovery Life Sciences LLC, Metabolon Inc., Caprion Proteomics Inc., Canopy Biosciences LLC
Download The Full Report For Exclusive Market Findings:
Which Regional Markets Are Contributing Most To The Biomarker Clinical Phase Outsourcing Services Industry Expansion?
North America was the largest region in the biomarker clinical phase outsourcing services market in 2024. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request A Customized Version Of The Biomarker Clinical Phase Outsourcing Services Market Report:
https://www.thebusinessresearchcompany.com/customise?id=15740&type=smp
Browse Through More Reports Similar to the Global Biomarker Clinical Phase Outsourcing Services Market 2025, By The Business Research Company
Bioadhesives Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/bioadhesives-global-market-report
Biosurfactants Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/biosurfactants-global-market-report
Probiotics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/probiotics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model